Abstract
Macrobiomolecular treatments for ocular inflammatory diseases have been described in a previous review. This article mainly discusses the application of small molecules in uveitis therapy, which includes corticosteroids, salicylic acid (aspirin), metabolite analogs, and anti-oxidative agents. Additionally, we update recent advances in peptide and nucleic acid related therapies, and focus mainly on the calcineurin inhibitor, cyclosporine, oral tolerant retinal proteins/peptides, gene therapy and ribonucleic acid interference strategies. We classify these immunomodulatory agents by their molecular signatures and highlight the molecular structure and mechanisms of function. These developments in understanding molecular mechanisms of the diseases, with the advent of new technologies, advance current therapeutic approaches. The future direction is to tailor treatments to individual patients in order to provide the safest and most effective therapies for ocular inflammatory diseases.
Keywords: Uveitis, macrobiomolecule, small molecule, immunosuppresion, anti-inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Application of Small Molecules/Macromolecules in Ocular Inflammatory Diseases
Volume: 11 Issue: 2
Author(s): Baoying Liu, Chi-Chao Chan and Robert B. Nussenblatt
Affiliation:
Keywords: Uveitis, macrobiomolecule, small molecule, immunosuppresion, anti-inflammation
Abstract: Macrobiomolecular treatments for ocular inflammatory diseases have been described in a previous review. This article mainly discusses the application of small molecules in uveitis therapy, which includes corticosteroids, salicylic acid (aspirin), metabolite analogs, and anti-oxidative agents. Additionally, we update recent advances in peptide and nucleic acid related therapies, and focus mainly on the calcineurin inhibitor, cyclosporine, oral tolerant retinal proteins/peptides, gene therapy and ribonucleic acid interference strategies. We classify these immunomodulatory agents by their molecular signatures and highlight the molecular structure and mechanisms of function. These developments in understanding molecular mechanisms of the diseases, with the advent of new technologies, advance current therapeutic approaches. The future direction is to tailor treatments to individual patients in order to provide the safest and most effective therapies for ocular inflammatory diseases.
Export Options
About this article
Cite this article as:
Liu Baoying, Chan Chi-Chao and B. Nussenblatt Robert, Application of Small Molecules/Macromolecules in Ocular Inflammatory Diseases, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2012; 11 (2) . https://dx.doi.org/10.2174/187152312803305713
DOI https://dx.doi.org/10.2174/187152312803305713 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment
Recent Patents on Anti-Cancer Drug Discovery Development and Characterization of Doxorubicin Bearing Vitamin B12 Coupled Sterically Stabilized Liposomes for Tumor Targeting
Current Nanoscience Natural Products and Cancer Stem Cells
Current Pharmaceutical Design Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets The Role of Platelet/Lymphocyte Serotonin Transporter in Depression and Beyond
Current Drug Targets Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Latest Advancements on Serotonin and Dopamine Transporters in Lymphocytes
Mini-Reviews in Medicinal Chemistry When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets
Current Pharmaceutical Design MicroRNA and Cancer: Tiny Molecules with Major Implications
Current Genomics Double Point Modified Analogs of Vitamin D as Potent Activators of Vitamin D Receptor
Current Pharmaceutical Design High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders
Current HIV Research Docking Studies of Glutamine Valproic Acid Derivative (S)-5- amino-2-(heptan-4-ylamino)-5-oxopentanoic Acid (Gln-VPA) on HDAC8 with Biological Evaluation in HeLa Cells
Anti-Cancer Agents in Medicinal Chemistry Optimized Radial Basis Neural Network for Classification of Breast Cancer Images
Current Medical Imaging Comparison of Pharmacodynamics and Celiac Effects of Olmesartan Medoxomil Formulations by using Olmesartan-induced Celiac-rat-model
Current Drug Delivery Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Current Pharmaceutical Design MDM2 Inhibitors for Pancreatic Cancer Therapy
Mini-Reviews in Medicinal Chemistry